MDMA therapy wait goes on as FDA panel rejects Lykos’ PTSD treatment
An FDA advisory committee, whilst noting improvement in patient symptoms, was not convinced by Lykos’ trial design.
An FDA advisory committee, whilst noting improvement in patient symptoms, was not convinced by Lykos’ trial design.
What's Your Reaction?
